PEOPLE - Inovio Biomedical makes appointment:
This article was originally published in Clinica
Executive Summary
Selective electrochemical tumour ablation (SECTA) therapy device developer Inovio Biomedical has named Michael Fons as vice-president of corporate development. SECTA is an alternative to localised surgical tumour removal. HTA, markets and IP specialist Dr Fons had been executive director at the San Diego, California company for some three years.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.